Q2 2015 13F Holders as of 30 Jun 2015
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
20,950,250
-
Share change
-
+20,471,396
-
Total reported value
-
$384,020,000
-
Price per share
-
$18.33
-
Number of holders
-
45
-
Value change
-
+$375,243,000
-
Number of buys
-
44
Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q2 2015
As of 30 Jun 2015,
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) was held by
45 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,950,250 shares.
The largest 10 holders included
FMR LLC, ORBIMED ADVISORS LLC, Novo A/S, Foresite Capital Management II, LLC, Capital World Investors, Partner Fund Management, L.P., Rock Springs Capital Management LP, ARROWGRASS CAPITAL PARTNERS (US) LP, QVT Financial LP, and JENNISON ASSOCIATES LLC.
This page lists
45
institutional shareholders reporting positions in this security
for the Q2 2015 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.